Browse CEACAM5

Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor, GPI-anchor
Domain PF13895 Immunoglobulin domain
PF07686 Immunoglobulin V-set domain
Function

Cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. Receptor for E.coli Dr adhesins.

> Gene Ontology
 
Biological Process GO:0010830 regulation of myotube differentiation
GO:0010832 negative regulation of myotube differentiation
GO:0014902 myotube differentiation
GO:0034109 homotypic cell-cell adhesion
GO:0042692 muscle cell differentiation
GO:0043276 anoikis
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051148 negative regulation of muscle cell differentiation
GO:0051153 regulation of striated muscle cell differentiation
GO:0051154 negative regulation of striated muscle cell differentiation
GO:2000209 regulation of anoikis
GO:2000811 negative regulation of anoikis
Molecular Function GO:0005543 phospholipid binding
GO:0034235 GPI anchor binding
GO:0035091 phosphatidylinositol binding
GO:0051861 glycolipid binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0016323 basolateral plasma membrane
GO:0031225 anchored component of membrane
GO:0031233 intrinsic component of external side of plasma membrane
GO:0071575 integral component of external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-109582: Hemostasis
R-HSA-392499: Metabolism of proteins
R-HSA-163125: Post-translational modification
R-HSA-597592: Post-translational protein modification
Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CEACAM5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CEACAM5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29686080Prostate CarcinomaPromote immunityAs a proof of concept, engineered chimeric antigen receptor T cells targeting CEACAM5 induced antigen-specific cytotoxicity in NEPC cell lines.
18624349Colorectal CancinomaPromote immunityEfficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells. In this study, we compared B cells and DC, after electroporation with carcinoembryonic antigen (CEA) RNA, for their capacity to generate cytotoxic T lymphocytes and antitumor immunity.
22750462Pancreatic AdenocarcinomaPromote immunityCarcinoembryonic antigen (CEA) is highly expressed on the surface of pancreatic adenocarcinoma cells; we investigated the effects of cytolytic T cells that recognize CEA in a mouse model of pancreatic carcinoma. Injection of the anti-CEA CAR T cells reduced the size of pancreatic tumors to below the limit of detection in all mice and produced long-term tumor eradication in 67% of mice. T cells also eradicated CEA(+) fibrosarcoma cells injected 45 days later. Injection of T cells that target CEA can eradicate tumors grown from CEA(+) pancreatic carcinoma cells in the pancreas of CEAtg mice without autoimmune effects.
16170184Colorectal CarcinomaPromote immunityPhase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. With a median follow-up of 64 months, the median OS time from the first liver resection for RAIT patients was 68.0 months (95% CI, 46.0 months to infinity), and the median DFS time was 18.0 months (95% CI, 11.0 to 31.0 months).
Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CEACAM5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CEACAM5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3950.272
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0650.921
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7390.214
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4480.691
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9120.678
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472.1450.338
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.7110.485
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3310.853
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.1150.566
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1790.723
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CEACAM5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.46.80.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.53.76.80.393
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CEACAM5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CEACAM5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CEACAM5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CEACAM5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CEACAM5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CEACAM5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCEACAM5
Namecarcinoembryonic antigen-related cell adhesion molecule 5
Aliases CD66e; meconium antigen 100; CD antigen CD66e; Carcinoembryonic antigen
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CEACAM5 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CEACAM5.
ID Name Drug Type Targets #Targets
DB08217S-[(1-Hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioateSmall MoleculeCEACAM5, EIF4E2